ID | 61734 |
フルテキストURL | |
著者 |
Laukhtina, Ekaterina
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Pradere, Benjamin
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Mori, Keiichiro
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Schuettfort, Victor M.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Quhal, Fahad
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Mostafaei, Hadi
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Sari Motlangh, Reza
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Katayama, Satoshi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Grossmann, Nico C.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
Moschini, Marco
Department of Urology, Luzerner Kantonsspital
Enikeev, Dmitry
Institute for Urology and Reproductive Health, Sechenov University,
Shariat, Shahrokh F.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
|
抄録 | PURPOSE
The present systematic review aimed to identify prognostic values of tissue-based biomarkers in patients treated with neoadjuvant systemic therapy (NAST), including chemotherapy (NAC) and checkpoint inhibitors (NAI) for urothelial carcinoma of the bladder (UCB). MATERIAL AND METHODS The PubMed, Web of Science, and Scopus databases were searched in August 2020 according to the PRISMA statement. Studies were deemed eligible if they compared oncologic or pathologic outcomes in patients treated with NAST for UCB with and without detected pretreatment tissue-based biomarkers. RESULTS Overall, 44 studies met our eligibility criteria. Twenty-three studies used immunohistochemistry (IHC), 19 – gene expression analysis, three - quantitative polymerase chain reaction (QT PCR), and two – next-generation sequencing (NGS). According to the currently available literature, predictive IHC-assessed biomarkers, such as receptor tyrosine kinases and DNA repair pathway alterations, do not seem to convincingly improve our prediction of pathologic response and oncologic outcomes after NAC. Luminal and basal tumor subtypes based on gene expression analysis showed better NAC response, while claudin-low and luminal-infiltrated tumor subtypes did not. In terms of NAI, PD-L1 seems to maintain value as a predictive biomarker, while the utility of both tumor mutational burden and molecular subtypes remains controversial. Specific genomic alterations in DNA repair genes have been shown to provide significant predictive value in patient treated with NAC. QT PCR quantification of specific genes selected through microarray analysis seems to classify cases regarding their NAC response. CONCLUSION We believe that the present systematic review may offer a robust framework that will enable the testing and validation of predictive biomarkers in future prospective clinical trials. NGS has expanded the discovery of molecular markers that are reflective of the mechanisms of the NAST response. |
キーワード | Biomarkers
UCB
bladder cancer
Neoadjuvant systemic therapy
NAC
systematic review
|
発行日 | 2021-03-31
|
出版物タイトル |
Urologic Oncology: Seminars and Original Investigations
|
巻 | 39巻
|
号 | 3号
|
出版者 | Elsevier
|
開始ページ | 180
|
終了ページ | 190
|
ISSN | 10781439
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2021 The Authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1016/j.urolonc.2020.12.019
|
ライセンス | http://creativecommons.org/licenses/by/4.0/
|
Citation | Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlangh R, Katayama S, Grossmann NC, Moschini M, Enikeev D, Shariat SF; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. Urol Oncol. 2021 Mar;39(3):180-190. doi: 10.1016/j.urolonc.2020.12.019. Epub 2021 Jan 8. PMID: 33423937.
|
オープンアクセス(出版社) |
OA
|
オープンアーカイブ(出版社) |
非OpenArchive
|